Clinical Trial Update: Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating an EGFR tyrosine kinase inhibitor in patients with advanced non-small cell lung cancer carrying EGFR mutations. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR tyrosine kinase inhibitor (investigational)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: NSCLC | Phase 2 | Status: RECRUITING